Showing results (461-470 of 490) with videos related to

Sort By:
Pageof 49
The Journal of Clinical Investigation|August 14, 2019
Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman diseaseDavid C Fajgenbaum, Ruth-Anne Langan, Alberto Sada Japp, et al.
Blood|March 12, 2016
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineagesJean-François Emile, Oussama Abla, Sylvie Fraitag, et al.
NAR Cancer|July 28, 2021
Ribosomal RNA 2'O-methylation as a novel layer of inter-tumour heterogeneity in breast cancerVirginie Marcel, Janice Kielbassa, Virginie Marchand, et al.
Plos One|July 14, 2021
Seroprevalence of SARS-CoV-2 infection in Cincinnati Ohio USA from August to December 2020Greg Davis, Allen J York, Willis Clark Bacon, et al.
Blood Advances|October 20, 2021
High risk of relapsed disease in patients with NK/T-cell chronic active Epstein-Barr virus disease outside of AsiaBlachy J Dávila Saldaña, Tami John, Challice Bonifant, et al.
BMC Cancer|May 11, 2022
Low level of Fibrillarin, a ribosome biogenesis factor, is a new independent marker of poor outcome in breast cancerFlora Nguyen Van Long, Audrey Lardy-Cleaud, Dimitri Carène, et al.
The Journal of Allergy and Clinical Immunology|January 17, 2020
Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (DADA2)Pui Y Lee, Erinn S Kellner, Yuelong Huang, et al.
The Journal of Allergy and Clinical Immunology|April 12, 2025
Lipopolysaccharide-responsive and beige-like anchor protein (LRBA) functional deficiency caused by biallelic LRBA missense variants characterized by Evans syndrome or colitisSamuel C C Chiang, Li Yang, Erika Owsley, et al.
Annals of the Rheumatic Diseases|July 24, 2023
The 2022 EULAR/ACR points to consider at the early stages of diagnosis and management of suspected haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS)Bita Shakoory, Ashley Geerlinks, Marta Wilejto, et al.
Blood Advances|April 12, 2023
Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCTAshley V Geerlinks, Brooks Scull, Christa Krupski, et al.
Pageof 49